SUMMARY 4 -- 1. INTRODUCTION 4 -- 2. OBJECTIVES AND SCOPE 5 -- 3. METHODS 5 -- 3.1. THE SEARCH FOR CLINICAL PRACTICE GUIDELINES 5 -- 3.2. UPDATE SEARCH 5 -- 3.3. QUALITY APPRAISAL 5 -- 3.4. DATA EXTRACTION AND EVIDENCE SUMMARY 5 -- 3.5. GRADING OF EVIDENCE 6 -- 3.6. ELABORATION OF THE FINAL RECOMMENDATIONS 6 -- 3.7. VALIDATION OF THE GUIDELINE 6 -- 4. CLINICAL RECOMMENDATIONS 7 -- 4.1. DIAGNOSIS AND STAGING 7 -- 4.1.1. Staging of lung cancer 7 -- 4.1.2. Pathology and molecular testing 9 -- 4.2. TREATMENT OF NSCLC 10 -- 4.2.1. Treatment of early stage NSCLC (stage cI-II and selected stage cIIIA cT3N1) 10 -- 4.2.2. Treatment of stage cIII NSCLC 13 -- 4.2.3. Tumours involving the parietal pleura or the chest wall, and sulcus superior tumours 14 -- 4.2.4. Treatment of metastatic (stage cIV) and recurrent NSCLC 14 -- 4.2.5. Follow-up 15 -- 4.3. TREATMENT OF SCLC 16 -- 4.3.1. ‘Limited-stage disease’ SCLC (broadly corresponding to T1-4, N0-3,M0) 16 -- 4.3.2. ‘Extensive stage disease’ SCLC (broadly corresponding to T1-4, N0-3, M1a/b – -- including cerebral metastases) 17 -- 4.3.3. Relapsed SCLC 17 -- 5. IMPLEMENTATION AND UPDATING OF THE GUIDELINE 18 -- 5.1. IMPLEMENTATION 18 -- 5.2. MONITORING THE QUALITY OF CARE 18 -- 5.3. GUIDELINE UPDATE 18 -- POLICY RECOMMENDATIONS 19 -- REFERENCES 21